Skip directly to search Skip directly to A to Z list Skip directly to site content
CDC Home

Volume 10, Number 1—January 2004

Research

Respiratory and Urinary Tract Infections, Arthritis, and Asthma Associated with HTLV-I and HTLV-II Infection

Edward L. Murphy*, Baoguang Wang†, Ronald A. Sacher‡, Joy Fridey§, James W. Smith¶, Catharie C. Nass#, Bruce Newman**, Helen E. Ownby**, George Garratty††, Sheila T. Hutching††, and George B. Schreiber†
Author affiliations: *University of California San Francisco, California, USA; †Westat, Rockville, Maryland, USA; ‡Hoxworth Blood Center, Cincinnati, Ohio, USA; §Blood Bank of San Bernardino and Riverside Counties, San Bernardino, California, USA; ¶Oklahoma Blood Institute, Oklahoma City, Oklahoma, USA; #American Red Cross Blood Services Chesapeake and Potomac, Baltimore, Maryland, USA; **American Red Cross Blood Services Southeastern Michigan, Detroit, Michigan, USA; ††American Red Cross Blood Services Southern California, Los Angeles, California, USA

Main Article

Table 4

Prevalence of medically diagnosed symptoms, and unadjusted and adjusted odds ratios (OR) derived from logistic regression models, in human T-lymphotropic virus (HTLV)-I– and HTLV-II–infected participants and HTLV-seronegative participants, visits 2 and 3a

Symptoms HTLV seronegative 
(N = 799) HTLV-I (N = 152) HTLV-II (N = 387)
Cases (%)b Cases (%)b ORc Adj. OR (95% CI)d Cases (%)b ORc Adj. OR (95% CI)d
Trouble walking, climbing or rising from chair 147 (21) 52 (42) 2.71 2.67 (1.74 to 4.09) 133 (42) 2.78 3.44 (2.52 to 4.71)
Incontinence, pre- or post-void urgency 175 (25) 50 (40) 2.03 2.02 (1.33 to 33.07) 134 (43) 2.25 2.59 (1.92 to 3.49)
Lymphadenopathy 29 (4) 11 (9) 2.26 2.39 (1.14 to 5.03) 40 (13) 3.40 3.08 (1.85 to 5.13)
Night sweats 20 (3) 15 (12) 4.68 4.73 (2.31 to 9.69) 47 (15) 6.02 4.97 (2.77 to 8.94
Weight loss 40 (6) 9 (7) 1.29 1.10 (0.51 to 2.37) 40 (13) 2.43 2.10 (1.22 to 3.60)
Foot paresthesias 57 (8) 22 (18) 2.44 2.46 (1.41 to 4.28 66 (21) 3.02 3.27 (2.19 to 4.88)
Impotence (males only) 33 (5) 10 (8) 2.24 2.05 (0.77 to 5.49) 13 (4) 1.10 1.27 (0.56 to 2.91)

aOnly the first diagnosis of each symptom is considered for each participant.
bDenominator for percentage calculation varied according to the number of participants included in each disease-specific analysis.
cUnadjusted.
dAdjusted. Models were adjusted for age, race and ethnicity, and duration of follow-up (all symptoms), and gender (all except impotence). In addition, specific models included community versus autologous donation (for trouble walking and incontinence, weight loss and impotence.) and injection drug use [night sweats and weight loss]).

Main Article

Top of Page

USA.gov: The U.S. Government's Official Web PortalDepartment of Health and Human Services
Centers for Disease Control and Prevention   1600 Clifton Rd. Atlanta, GA 30333, USA
800-CDC-INFO (800-232-4636) TTY: (888) 232-6348 - Contact CDC–INFO